Moderna Inc (MRNA) Projects $1.9 Billion Revenue for 2025, Shares Surge 12.8%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy MRNA?
Source: Benzinga
- Revenue Forecast Increase: At the 44th Annual J.P. Morgan Healthcare Conference, Moderna announced an expected revenue of approximately $1.9 billion for 2025, which is $100 million above the previously communicated midpoint, enhancing investor confidence and driving stock price up.
- Operating Expense Improvement: The company also lowered its projected GAAP operating expenses for 2025 by $200 million, demonstrating improved cost control capabilities that lay a solid foundation for future profitability.
- Increased Cash Balance: Moderna anticipates an end-of-year cash balance of approximately $8.1 billion, providing strong support for the company's R&D and market expansion efforts, further solidifying its market position.
- Strong Stock Performance: Following the positive news, Moderna's stock surged 12.8% to $38.20 on Tuesday, reflecting market optimism regarding its future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 53.570
Low
17.00
Averages
32.47
High
63.00
Current: 53.570
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
EMA Recommends Moderna's Combined COVID-19 and Influenza Vaccine
- Vaccine Approval Recommendation: The European Medicines Agency has recommended marketing authorization for Moderna's combined COVID-19 and influenza vaccine, mCombriax, highlighting its significance for the elderly population.
- Clinical Trial Data: The recommendation is based on data from 8,000 individuals aged 50 and older, demonstrating that antibody levels against flu and SARS-CoV-2 were non-inferior to those receiving the COVID vaccine Spikevax and flu vaccines Fluzone HD or Fluarix, indicating its efficacy.
- Market Potential: Targeting individuals aged 50 and older, mCombriax addresses the dual protection needs of the elderly, which is expected to drive further growth for Moderna in the vaccine market.
- Regulatory Dynamics: Although Moderna withdrew its application with the US FDA in May 2025, the EMA's recommendation may pave the way for future global market promotion of the vaccine.
See More
MODERNA EXPECTS BROADER ACCESS TO MCOMBRIAX IN THE EU BY 2027
Moderna's Anticipated Expansion: Moderna is planning to make its mRNA vaccine, Comirnaty, more widely available by 2027.
Focus on Accessibility: The company aims to enhance the distribution and accessibility of its vaccine to a broader population.
See More
Novavax Executive Expresses Optimism About Moderna's Advancements in Flu Vaccine Development
- Novavax's Response: Novavax executives express optimism about their flu vaccine development, encouraged by the progress made by Moderna in the same field.
- Industry Comparison: The executives highlight the advancements in vaccine technology and the competitive landscape, particularly noting Moderna's achievements as a motivating factor.
See More
Salesforce Reports Strong Q4 Results, Stock Drops Amid AI Concerns
- Strong Performance: Salesforce reported Q4 2026 revenue of $11.2 billion, a 12% year-over-year increase that exceeded market expectations of $11.18 billion, indicating robust growth potential driven by its Agentforce AI platform.
- Adjusted EPS Beat: The adjusted earnings per share reached $3.81, surpassing the consensus estimate by 77 cents and reflecting a 37% year-over-year increase, although overall margin performance was mixed with GAAP results falling short of expectations.
- Agentforce Platform Success: Since its launch, the Agentforce platform has closed over 29,000 deals, generating $800 million in annual recurring revenue, highlighting its significance in enterprise transformation, despite ongoing market skepticism about its long-term growth potential.
- Future Guidance: Salesforce anticipates Q1 FY 2027 revenue between $11.03 billion and $11.08 billion, with adjusted EPS projected at $3.11 to $3.13, slightly above market expectations, yet overall guidance remains below analyst forecasts, reflecting concerns about growth sustainability.
See More
Moderna Faces Revenue Decline Amid Vaccine Demand Drop
- Vaccine Sales Decline: Moderna's revenue has significantly dropped due to the U.S. halting approximately $500 million in mRNA vaccine development funding last year, leading to a decline in investor confidence as sales fail to match pandemic peak levels.
- New Product Development: Despite challenges, Moderna received approval for its respiratory syncytial virus (RSV) vaccine in 2024 and plans to expand its seasonal vaccine portfolio, including a flu vaccine, aiming to drive future growth through product diversification.
- Regulatory Dynamics Shift: Although the FDA initially refused to review Moderna's flu vaccine application, the agency reversed its decision after the company proposed a revised regulatory approach, planning to reassess the candidate, which could provide new options for the upcoming flu season if successful.
- Long-Term Growth Outlook: Moderna expects to achieve cash breakeven by 2028 through seasonal vaccine sales and has reiterated its forecast for up to 10% revenue growth this year, indicating strong long-term potential in the biotechnology sector.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
EMA Recommends Moderna's Combined COVID-19 and Influenza Vaccine
- Vaccine Approval Recommendation: The European Medicines Agency has recommended marketing authorization for Moderna's combined COVID-19 and influenza vaccine, mCombriax, highlighting its significance for the elderly population.
- Clinical Trial Data: The recommendation is based on data from 8,000 individuals aged 50 and older, demonstrating that antibody levels against flu and SARS-CoV-2 were non-inferior to those receiving the COVID vaccine Spikevax and flu vaccines Fluzone HD or Fluarix, indicating its efficacy.
- Market Potential: Targeting individuals aged 50 and older, mCombriax addresses the dual protection needs of the elderly, which is expected to drive further growth for Moderna in the vaccine market.
- Regulatory Dynamics: Although Moderna withdrew its application with the US FDA in May 2025, the EMA's recommendation may pave the way for future global market promotion of the vaccine.
See More
MODERNA EXPECTS BROADER ACCESS TO MCOMBRIAX IN THE EU BY 2027
Moderna's Anticipated Expansion: Moderna is planning to make its mRNA vaccine, Comirnaty, more widely available by 2027.
Focus on Accessibility: The company aims to enhance the distribution and accessibility of its vaccine to a broader population.
See More
Novavax Executive Expresses Optimism About Moderna's Advancements in Flu Vaccine Development
- Novavax's Response: Novavax executives express optimism about their flu vaccine development, encouraged by the progress made by Moderna in the same field.
- Industry Comparison: The executives highlight the advancements in vaccine technology and the competitive landscape, particularly noting Moderna's achievements as a motivating factor.
See More
Salesforce Reports Strong Q4 Results, Stock Drops Amid AI Concerns
- Strong Performance: Salesforce reported Q4 2026 revenue of $11.2 billion, a 12% year-over-year increase that exceeded market expectations of $11.18 billion, indicating robust growth potential driven by its Agentforce AI platform.
- Adjusted EPS Beat: The adjusted earnings per share reached $3.81, surpassing the consensus estimate by 77 cents and reflecting a 37% year-over-year increase, although overall margin performance was mixed with GAAP results falling short of expectations.
- Agentforce Platform Success: Since its launch, the Agentforce platform has closed over 29,000 deals, generating $800 million in annual recurring revenue, highlighting its significance in enterprise transformation, despite ongoing market skepticism about its long-term growth potential.
- Future Guidance: Salesforce anticipates Q1 FY 2027 revenue between $11.03 billion and $11.08 billion, with adjusted EPS projected at $3.11 to $3.13, slightly above market expectations, yet overall guidance remains below analyst forecasts, reflecting concerns about growth sustainability.
See More
Moderna Faces Revenue Decline Amid Vaccine Demand Drop
- Vaccine Sales Decline: Moderna's revenue has significantly dropped due to the U.S. halting approximately $500 million in mRNA vaccine development funding last year, leading to a decline in investor confidence as sales fail to match pandemic peak levels.
- New Product Development: Despite challenges, Moderna received approval for its respiratory syncytial virus (RSV) vaccine in 2024 and plans to expand its seasonal vaccine portfolio, including a flu vaccine, aiming to drive future growth through product diversification.
- Regulatory Dynamics Shift: Although the FDA initially refused to review Moderna's flu vaccine application, the agency reversed its decision after the company proposed a revised regulatory approach, planning to reassess the candidate, which could provide new options for the upcoming flu season if successful.
- Long-Term Growth Outlook: Moderna expects to achieve cash breakeven by 2028 through seasonal vaccine sales and has reiterated its forecast for up to 10% revenue growth this year, indicating strong long-term potential in the biotechnology sector.
See More
